QVT buys Biosynexus

Biosynexus, a biotechnology-pharmaceutical company that is commercializing a portfolio of products for the prevention and treatment of infectious diseases, has been acquired for an unspecified sum by the QVT Fund. Biosynexus also announced that Dr. Irwin Scher has been appointed CEO. "It is very exciting to be joining a company with such tremendous potential, and to be coming on board with QVT Fund LP as our parent company," said Dr. Scher. "This will provide us with the additional capital for completing our clinical trials and for further investment in, and expansion of, our current pipeline."

- read this press release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.